Biotherapeutics for cancers and infectious disease using PIKA® immunomodulating technology; influencing innate and adaptive immune responses through TLR3, RIG-I and MDA5 pathways. Products in devt include YS-ON-001 (Ph 1), an IO product targeting solid tumors and new gen of biologics for preventive and therapeutic benefits, incl YS-HBV-001 (Ph 1) and PIKA rabies vaccine (Ph 3), targeting hep B and rabies infections. PC programs incl biologics targeting influenza, herpes zoster, ebola, et al. 2 biologics products on mkt. HQ in Beijing, 640 employees WW.
9 Tianfu Street
Building 10, Room 309
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.